Nepsone is a preclinical-stage pharmaceutical company developing drugs to treat dermatological conditions that arise due to an imbalance in the autonomic nervous system.

Currently, these conditions are believed to originate in the immune system. Nepsone foundational neuroimmunology theory on the origin of psoriasis teaches us that an imbalance in neuropeptide activity in the body leads to these conditions.

Our drugs are designed to utilize the body’s natural mechanisms to bring back balance and alleviate the disease.

Technology Development Fund (Rannís)

Nepsone ehf has been awarded a grant from Tækniþróunarsjóður (Technology Development Fund) of Rannís (The Icelandic Centre for Research).


Nepsone’s drug discovery platform can potentially address over 10 indications in total.

Psoriasis (Lead Indication)

Phase: Preclinical

Modalities: Topical and Systemic

Alopecia Areata

Phase: Research and Discovery

Modality: Topical

There are currently no approved drugs for the treatment of alopecia areata.

Eczema (Atopic Dermatitis)

Phase: Research and Discovery

Modality: Topical

The People of Nepsone

Bjarki Gudlaugsson


Svandis Kristjansdottir

Head of Clinical Development

Hakon Hrafn Sigurdsson

Head of R&D

Gunhild L Skovgaard

Head of Medical Affairs

Tomas Thorvaldsson

Chairman of the board

Birkir Sveinsson

Founder / Member of the board

Ragnar Bjarnason

Member of the board

Contact Us

Nepsone ehf.
Laugavegur 77
101 Reykjavik

+354 555 1634